Osoba D, Aaronson N K, Muller M, Sneeuw K, Hsu M A, Yung W K, Brada M, Newlands E
British Columbia Cancer Agency (Vancouver Cancer Centre, Canada.
J Neurooncol. 1997 Sep;34(3):263-78. doi: 10.1023/a:1005790632126.
The purpose of the study was to assess health-related quality of life (HQL) in patients with high-grade malignant glioma of the brain. The EORTC core Quality of Life Questionnaire (QLQ-C30) and a Brain Cancer Module (BCM20) were administered at baseline and several weeks later (follow-up) to 105 patients with either recently-diagnosed (n = 41) or recurrent (n = 64) malignant glioma. In addition, the attending neurologists completed a standard neurological examination, a modified Barthel Activities of Daily Living Index (BADLI) and the Karnofsky Performance Scale (KPS). In a preliminary step, the QLQ-C30 was found to have acceptable reliability (internal consistency and test-retest reliability). Newly-diagnosed patients and those with a KPS of 80-100 had significantly better physical, role and cognitive functioning and global quality of life with less fatigue, visual disorder, motor dysfunction, communication deficit, weakness of both legs and trouble controlling the bladder than did those with recurrent disease and those with a KPS of 50-70. Similarly, those capable of independent activities of daily living, as reported on the BADLI, had higher functioning scores and less fatigue than did those who were not independent. Patients with dysphasia, mental confusion or motor deficit on neurological examination reported significantly lower levels of physical, role, cognitive, emotional and social functioning and global quality of life than did patients not having these difficulties. They also had significantly more symptoms. In patients with deteriorating neurological status between baseline and follow-up, there was a marked decline in cognitive, physical, role, emotional and social functioning and global quality of life and an increase in fatigue. Thus, there are significant differences in HQL between patients with newly-diagnosed and recurrent brain cancer and between patients with differing KPS and BADLI scores. In addition, the HQL scores provide details not provided by the KPS and the BADLI. Deterioration in neurological function is accompanied by significant deterioration in a range of HQL domains and in global quality of life.
该研究的目的是评估脑高级别恶性胶质瘤患者的健康相关生活质量(HQL)。在基线时以及几周后(随访时),对105例新近诊断(n = 41)或复发(n = 64)的恶性胶质瘤患者使用了欧洲癌症研究与治疗组织核心生活质量问卷(QLQ-C30)和一个脑癌模块(BCM20)。此外,主治神经科医生完成了标准的神经学检查、改良的巴氏日常生活活动指数(BADLI)和卡氏功能状态评分(KPS)。在初步阶段,发现QLQ-C30具有可接受的信度(内部一致性和重测信度)。与复发疾病患者以及KPS为50 - 70的患者相比,新近诊断的患者以及KPS为80 - 100的患者在身体、角色和认知功能以及总体生活质量方面显著更好,疲劳、视觉障碍、运动功能障碍、沟通缺陷、双腿无力和膀胱控制问题更少。同样,正如BADLI所报告的,能够独立进行日常生活活动的患者比不能独立的患者功能得分更高且疲劳更少。在神经学检查中存在言语困难、精神错乱或运动缺陷的患者在身体、角色、认知、情感和社会功能以及总体生活质量方面的水平显著低于没有这些困难的患者。他们的症状也明显更多。在基线和随访之间神经状态恶化的患者中,认知、身体、角色、情感和社会功能以及总体生活质量显著下降,疲劳增加。因此,新近诊断和复发脑癌患者之间以及不同KPS和BADLI评分的患者之间在HQL方面存在显著差异。此外,HQL评分提供了KPS和BADLI未提供的详细信息。神经功能的恶化伴随着一系列HQL领域以及总体生活质量的显著恶化。